Skip to content

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation

Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07174622
Acronym
SPYRAL CARE
Enrollment
1000
Registered
2025-09-16
Start date
2025-10-28
Completion date
2029-06-01
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Hypertension, Vascular Diseases

Brief summary

This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.

Detailed description

The SPYRAL CARE study is an observational, non-interventional study of the Medicare population with uncontrolled hypertension treated with either the Symplicity RDN system plus standard of care (SOC) or with SOC alone. SOC reflects active management of hypertension. The study will evaluate real-world clinical outcomes by examining deidentified, longitudinal data from administrative health insurance claims linked with EHR. The primary objective is to assess the change in office systolic blood pressure at two years for patients treated with Symplicity RDN plus SOC compared to similar patients receiving SOC alone. The secondary objective is to describe major adverse cardiac events over a two-year period in both groups. The study analysis is subject to a central Institutional Review Board (IRB) review. However, individual hospitals are not engaged in research, and local IRB oversight is not necessary.

Interventions

Symplicity Spyral™ multi-electrode renal denervation system

Sponsors

Medtronic Vascular
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Enrolled in a Medicare plan * Diagnosis of uncontrolled hypertension * On a stable regimen of antihypertensive therapy

Exclusion criteria

* A prior RDN procedure * Diagnosis of secondary hypertension * Any condition for which RDN is contraindicated

Design outcomes

Primary

MeasureTime frameDescription
Change in Office Systolic Blood Pressure (OSBP)2 yearsChange in OSBP at two years relative to baseline between matched treated and comparator cohorts.

Secondary

MeasureTime frameDescription
Time to Major Cardiovascular Event (MACE)2 yearsThe secondary outcome is time to MACE over 2 years for the matched treated and comparator cohorts. MACE is defined as the composite of non-fatal stroke, non-fatal myocardial infarction, and all-cause death.

Countries

United States

Contacts

CONTACTKael Wherry, PhD, MS
kael.wherry@medtronic.com612-229-0714
PRINCIPAL_INVESTIGATOREric A Secemsky, MD, MSc

Beth Israel Deaconess Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026